Trichoscopy for scalp involvement in systemic scleroderma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study using trichoscopy—a simple, reproducible, noninvasive dermoscopic exam—to document scalp findings in adults who meet the 2013 ACR-EULAR criteria for systemic scleroderma. Investigators will take standardized trichoscopic images and photographs of the scalp and compare those findings with patients' clinical features and systemic disease manifestations. A control group without active inflammatory scalp disease will be used for comparison. Data collection will include clinical history, disease features, and imaging to explore associations between scalp abnormalities and scleroderma characteristics.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient who fulfils the Systemic scleroderma ACR-EULAR 2013 criteria
* Signed informed consent
* Being social insured

Exclusion Criteria:

* Patients aged less than 18 years old
* patients under legal protection
* patients deprived of their liberty
* patients in emergency situations
* patients who refused or unable to give informed consent
* For the control group: sclap inflammatory disease active the day of the examination

Where it's running

• Hop Claude Huriez Chu Lille
  Lille, France Recruiting

Study contacts

• Principal investigator: Vincent Sobanski, MD — University Hospital, Lille
• Study coordinator: Vincent Sobanski, MD
• Email: vincent.sobanski@chru-lille.fr
• Phone: 0320445962

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-in-human test of PRO-203 in healthy adults and people with systemic sclerosis

  Researchers will test a single subcutaneous dose of PRO-203 in healthy adults and in people with systemic sclerosis to see if it is safe and how the body handles it.

  Recruiting at 12 sites Phase 1/2 Prolium Bioscience, Inc · Melbourne, Victoria and 12 other locations · NCT07641634

• Anti-CD19 CAR T-cell therapy for severe systemic sclerosis that didn’t respond to standard treatment

  This study tests whether a patient’s own anti-CD19 CAR T-cells can help reduce skin thickening and other disease activity in adults with active, treatment-resistant systemic sclerosis.

  Recruiting Phase 2 University Hospital, Montpellier · Lille and 3 other locations · NCT07493395

• Western Sweden Systemic Sclerosis Project

  This project will collect blood, skin and DNA samples from people with systemic sclerosis in Western Sweden to try to find genes, proteins, and immune changes linked to how the disease starts and gets worse.

  Recruiting Sahlgrenska University Hospital · Gothenburg, Sweden · NCT07345052

• Biopsychosocial (BETY) exercise program for children and adults with scleroderma

  This project will test whether BETY, a biopsychosocial exercise program, helps children and adults with scleroderma improve physical function and psychosocial well-being.

  Recruiting Hacettepe University · Ankara, Altındağ · NCT07292961

• Diosmin for healing finger (digital) ulcers in scleroderma

  This study will test whether the pill diosmin can safely help heal open finger ulcers in people with systemic sclerosis.

  Recruiting at 5 sites Primus Pharmaceuticals · Calgary, Alberta and 4 other locations · NCT06256575

• Mouth bacteria in systemic sclerosis

  This project will test whether the bacteria living under the gums differ in adults with early systemic sclerosis compared with routine dental patients.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT06182293

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.